Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT: Problem solving by diffusion whole-body MRI

Giorgio Conte; Fabio Zugni; Marco Colleoni; Giuseppe Renne; Massimo Bellomi; Giuseppe Petralia

doi:10.3332/ecancer.2015.537

Sarcoidosis with bone involvement mimicking metastatic disease at ¹⁸F-FDG PET/CT: Problem solving by diffusion whole-body MRI

Giorgio Conte, Fabio Zugni, Marco Colleoni, Giuseppe Renne, Massimo Bellomi, Giuseppe Petralia

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

Bone involvement has been reported in 1-13% of patients with sarcoidosis. Both 18F-fluorodeoxyglucose (¹⁸F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) and conventional magnetic resonance imaging (MRI) are sensitive in detecting sarcoidosis bone lesions, but are not always reliable in differentiating sarcoidosis bone lesions from metastatic disease, thus often requiring bone biopsy. We describe the use of diffusion whole-body MRI for bone assessment in a patient with breast cancer and sarcoidosis, presenting with bone marrow lesions mimicking metastatic disease at ¹⁸F-FDG PET/CT. In our case, diffusion whole-body MRI represented a useful tool for bone assessment and overcame the limitation of ¹⁸F-FDG PET/CT in discriminating inflammatory bone marrow involvement from metastatic disease.

Original language	English
Article number	537
Journal	ecancermedicalscience
Volume	9
DOIs	https://doi.org/10.3332/ecancer.2015.537
Publication status	Published - May 7 2015

Keywords

Bone
Diffusion weighted imaging
Metastasis
Sarcoidosis
Whole body imaging

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3332/ecancer.2015.537

Cite this

@article{c959daffc0334a93bc512a7e8c856119,

title = "Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT: Problem solving by diffusion whole-body MRI",

abstract = "Bone involvement has been reported in 1-13% of patients with sarcoidosis. Both 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) and conventional magnetic resonance imaging (MRI) are sensitive in detecting sarcoidosis bone lesions, but are not always reliable in differentiating sarcoidosis bone lesions from metastatic disease, thus often requiring bone biopsy. We describe the use of diffusion whole-body MRI for bone assessment in a patient with breast cancer and sarcoidosis, presenting with bone marrow lesions mimicking metastatic disease at 18F-FDG PET/CT. In our case, diffusion whole-body MRI represented a useful tool for bone assessment and overcame the limitation of 18F-FDG PET/CT in discriminating inflammatory bone marrow involvement from metastatic disease.",

keywords = "Bone, Diffusion weighted imaging, Metastasis, Sarcoidosis, Whole body imaging",

author = "Giorgio Conte and Fabio Zugni and Marco Colleoni and Giuseppe Renne and Massimo Bellomi and Giuseppe Petralia",

year = "2015",

month = may,

day = "7",

doi = "10.3332/ecancer.2015.537",

language = "English",

volume = "9",

journal = "ecancermedicalscience",

issn = "1754-6605",

publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Sarcoidosis with bone involvement mimicking metastatic disease at 18F-FDG PET/CT

T2 - Problem solving by diffusion whole-body MRI

AU - Conte, Giorgio

AU - Zugni, Fabio

AU - Colleoni, Marco

AU - Renne, Giuseppe

AU - Bellomi, Massimo

AU - Petralia, Giuseppe

PY - 2015/5/7

Y1 - 2015/5/7

N2 - Bone involvement has been reported in 1-13% of patients with sarcoidosis. Both 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) and conventional magnetic resonance imaging (MRI) are sensitive in detecting sarcoidosis bone lesions, but are not always reliable in differentiating sarcoidosis bone lesions from metastatic disease, thus often requiring bone biopsy. We describe the use of diffusion whole-body MRI for bone assessment in a patient with breast cancer and sarcoidosis, presenting with bone marrow lesions mimicking metastatic disease at 18F-FDG PET/CT. In our case, diffusion whole-body MRI represented a useful tool for bone assessment and overcame the limitation of 18F-FDG PET/CT in discriminating inflammatory bone marrow involvement from metastatic disease.

AB - Bone involvement has been reported in 1-13% of patients with sarcoidosis. Both 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) and conventional magnetic resonance imaging (MRI) are sensitive in detecting sarcoidosis bone lesions, but are not always reliable in differentiating sarcoidosis bone lesions from metastatic disease, thus often requiring bone biopsy. We describe the use of diffusion whole-body MRI for bone assessment in a patient with breast cancer and sarcoidosis, presenting with bone marrow lesions mimicking metastatic disease at 18F-FDG PET/CT. In our case, diffusion whole-body MRI represented a useful tool for bone assessment and overcame the limitation of 18F-FDG PET/CT in discriminating inflammatory bone marrow involvement from metastatic disease.

KW - Bone

KW - Diffusion weighted imaging

KW - Metastasis

KW - Sarcoidosis

KW - Whole body imaging

UR - http://www.scopus.com/inward/record.url?scp=84932621313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932621313&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2015.537

DO - 10.3332/ecancer.2015.537

M3 - Article

SN - 1754-6605

VL - 9

JO - ecancermedicalscience

JF - ecancermedicalscience

M1 - 537

ER -